BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15754377)

  • 1. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
    Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
    Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
    Simko V; Michael S; Prego V
    Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Balkau B; Eschwège E; Poupon R
    N Engl J Med; 1991 May; 324(22):1548-54. PubMed ID: 1674105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease.
    Kneppelhout JC; Mulder CJ; van Berge Henegouwen GP; de Vries RA; Brandt KH
    Neth J Med; 1992 Aug; 41(1-2):11-6. PubMed ID: 1407234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
    Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
    Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
    Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
    Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.
    Zhang H; Yang J; Zhu R; Zheng Y; Zhou Y; Dai W; Wang F; Chen K; Li J; Wang C; Li S; Liu T; Abudumijiti H; Zhou Z; Wang J; Lu W; Wang J; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():567-74. PubMed ID: 25632224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.